South Korean pharmaceutical company Hugel has announced the private placement of 985,217 common stock shares priced at KRW360,001.9 ($316.2) a share to raise KRW354.68bn ($311.52m) in gross proceeds.

Chinese pharmaceutical company Guangdong Zhongsheng Pharmaceutical has announced a public offering of medium-term notes due 2022 to raise up to CNY1.3bn ($191.64m) in proceeds.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Valeant Pharmaceuticals International has announced plans to divest its speciality drug business, Obagi Medical Products, to China-based fund Haitong International Zhonghua Finance Acquisition, for $190m.

“Chinese pharmaceutical company Guangdong Zhongsheng Pharmaceutical has announced a public offering of medium-term notes due 2022 to raise up to CNY1.3bn ($191.64m) in proceeds.”

The Canadian speciality pharmaceutical company will use the proceeds from the divesture to repay its term loan.

Thermo Fisher Scientific has announced three public offerings of floating rate senior notes and senior notes to raise €2.6bn ($2.98bn) in total.

The floating rate senior notes are due July 2019, while the senior notes are due 23 January 2026, 24 July 2029 and 24 July 2037, and carry a rate of 1.4%, 1.95% and 2.875% respectively.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Thermo Fisher is an equipment, analytical instruments and reagents provider based in the US.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact